Recent Advances in Mantle Cell Lymphoma
Jacqueline D. Barrientos, MD, MS, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the most recent advances in mantle cell lymphoma, as well as the challenges investigators still face in the field.
Jacqueline D. Barrientos, MD, MS, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the most recent advances in mantle cell lymphoma (MCL), as well as the challenges investigators still face in the field.
Acalabrutinib (Calquence), a second-generation Bruton's tyrosine kinase inhibitor, was approved by the FDA last year for the treatment of patients with mantle cell lymphoma following at least 1 prior therapy. This drug works similarly to ibrutinib (Imbruvica) in this patient population.
While this an exciting advancement in the field, Barrientos says that patients with MCL still have the issue of relapse. Researchers are currently looking for combination strategies that can achieve longer remission or progression-free survival in patients.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
